AstraZeneca Nabs CinCor’s Hypertension Asset In $1.3bn Acquisition
Potential Combination With Farxiga
The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.
You may also be interested in...
Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.
The SGLT2 inhibitor has won European approval for the treatment of chronic kidney disease and while rival AstraZeneca’s Farxiga has had a two-year head start in the space, Boehringer and Lilly could come out on top given Jardiance’s stronger sales records to date.
The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.